What is Delfi Diagnostics?
Delfi Diagnostics is a pioneering biotechnology firm specializing in early cancer detection through its proprietary Fragmentomics Platform. By analyzing cell-free DNA from liquid biopsy samples, the company provides a scalable, cost-effective approach to oncology screening. Its flagship offerings, including FirstLookLung and DELFI-TF, are designed to integrate seamlessly into existing healthcare workflows, providing clinicians and patients with actionable insights for early intervention and treatment monitoring. The company operates at the intersection of genomics, artificial intelligence, and cancer biology, aiming to redefine the standard of care in oncology through precision diagnostics.
How much funding has Delfi Diagnostics raised?
Delfi Diagnostics has raised a total of $325M across 2 funding rounds:
Series A
$100M
Series B
$225M
Series A (2021): $100M with participation from Windham Venture Partners, Samsara Biocapital, Illumina Ventures, Menlo Ventures, OrbiMed Advisors LLC, and AV8 Ventures
Series B (2022): $225M led by Brown Advisory, DFJ Growth, Point72, and Eli Lilly and Company Pvt
Key Investors in Delfi Diagnostics
OrbiMed Advisors LLC
A specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics with deep expertise in life sciences.
Illumina Ventures
A leader in genomics and precision health investing, dedicated to building an ecosystem that translates scientific innovation into impactful human health solutions.
Menlo Ventures
A prominent venture capital firm that partners with founders across multiple stages of scale, focusing on high-growth technology companies in sectors including frontier tech and enterprise software.
What's next for Delfi Diagnostics?
With the recent infusion of capital, Delfi Diagnostics is well-positioned to transition from a research-heavy development phase into a broader commercial expansion. The strategic focus will likely center on expanding the clinical utility of its Fragmentomics Platform, deepening partnerships with pharmaceutical entities, and accelerating the regulatory pathways for its diagnostic pipeline. As the company scales, it remains focused on improving patient outcomes by making high-quality cancer screening more accessible across diverse healthcare systems. The continued support from top-tier life science investors suggests a clear path toward market leadership in the precision health landscape.
See full Delfi Diagnostics company page
